Breaking News Instant updates and real-time market news.

NVS

Novartis

$91.05

0.29 (0.32%)

, MRTX

Mirati Therapeutics

$104.01

-1.5 (-1.42%)

16:31
07/09/19
07/09
16:31
07/09/19
16:31

Mirati, Novartis collaborate to evaluate MRTX849 in combo with TNO155

Mirati Therapeutics (MRTX) announced a clinical collaboration agreement with Novartis (NVS) to evaluate the combination of MRTX849, Mirati's investigational KRAS G12C inhibitor and TNO155, Novartis' investigational SHP2 inhibitor, in patients with advanced solid tumors that harbor KRAS G12C mutations. SHP2 is an important mediator of cellular signaling through the RAS/MAP kinase pathway and is frequently overactive in various types of cancer. Preclinical data has shown that the combination of a KRAS G12C inhibitor with a SHP2 inhibitor results in increased anti-tumor activity based on their complementary mechanisms of action. Under terms of the non-exclusive collaboration, Mirati will sponsor the trial and Novartis and Mirati will jointly oversee and share the costs of clinical development activities for the combined therapy. Novartis will provide TNO155 at no cost.

NVS

Novartis

$91.05

0.29 (0.32%)

MRTX

Mirati Therapeutics

$104.01

-1.5 (-1.42%)

  • 11

    Jul

  • 22

    Jul

  • 23

    Jul

  • 31

    Jul

  • 09

    Sep

  • 25

    Sep

NVS Novartis
$91.05

0.29 (0.32%)

06/03/19
06/03/19
DOWNGRADE

Perform
Aduro Biotech downgraded to Perform on lack of catalysts at Oppenheimer
As previously reported, Oppenheimer analyst Mark Breidenbach downgraded Aduro Biotech (ADRO) to Perform from Outperform given the company's lack of near-term catalysts. The analyst notes that Aduro's partner Novartis (NVS) presented initial clinical results from an ongoing Phase 1b trial of ADU-S100 in combination with spartalizumab in advanced tumors at ASCO. Given the pretreatment history of these patients, he cannot state with confidence that the responses observed were dependent on ADUS100, and the trial data suggests dosing has not yet been fully optimized. As Novartis continues to evaluate the STING agonist, Breidenbach anticipates an extended development timeline.
06/14/19
PIPR
06/14/19
NO CHANGE
Target $120
PIPR
Neutral
Price tag of Bluebird's Zynteglo 'hard to justify,' says Piper Jaffray
The $1.8M price tag of Bluebird Bio's Zynteglo is "hard to justify" given the $2.1M comp of Novartis' (NVS) Zolgensma, which treats children with a certain outcome of death, as opposed to a population where the majority of patients are adequately maintained on transfusions, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. In Zynteglo clinical trials, only 60 beta-thal patients have been enrolled and 16 sickle cell patients have ever been infused, the analyst points out. Yet, says Van Buren, the Street is modeling that Bluebird transplants thousands of patients with Zynteglo. He continues to believe uptake of the gene therapy will be challenging and keeps a Neutral rating on Bluebird Bio with a $120 price target.
06/18/19
06/18/19
DOWNGRADE

Hold
Regeneron downgraded to Hold at Argus on mounting threats to Eylea
As previously reported, Argus analyst Jasper Hellweg downgraded Regeneron (REGN) to Hold from Buy, saying that while the company has a "strong pipeline" with new recent indications for multiple products, its primary revenue driver Eylea is facing several competitive threats. The analyst notes that Novartis (NVS) could launch a biologic designed to treat Eylea's key indication of wet age-related macular degeneration by the end of Q2 and also notes that the drug's patents are set to expire in 2022 in China and Japan, 2023 in the U.S., and 2024 in Europe. Hellweg adds that he will return his Regeneron rating to Buy if the company demonstrates that it can offset the impact of reduced Eylea sales, which accounted for over 75% of total revenue in Q1.
06/28/19
PIPR
06/28/19
DOWNGRADE
Target $250
PIPR
Neutral
Biogen downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Christopher Raymond downgraded Biogen (BIIB) to Neutral from Overweight and lowered his price target for the shares to $250 from $280. The stock closed yesterday up $1.70 to $239.77. Piper's new neurologist survey data from Spherix Global Insights "spells bad news for both Tecfidera and Tysabri in the near and longer term," Raymond tells investors in a research note. For the first time in a long time, Tecfidera market share is projected to contract over the next six months, primarily at the hands of Novartis' (NVS) new entrant Mayzent, explains the analyst. Further, Raymond notes that while prior surveys have indicated a plateauing of Roche's (RHHBY) Ocrevus with Biogen's Tysabri "hanging in there," the most recent indications are for an accelerating Ocrevus with Tysabri the "clear loser." The analyst lowered his estimates for both Tecfidera and Tysabri and downgraded Biogen.
MRTX Mirati Therapeutics
$104.01

-1.5 (-1.42%)

06/07/19
GUGG
06/07/19
DOWNGRADE
GUGG
Neutral
Guggenheim downgrades Mirati to Neutral following near-tripling of stock
As previously reported, Guggenheim analyst Michael Schmidt downgraded Mirati Therapeutics (MRTX) to Neutral from Buy, noting that the shares have nearly tripled since data were presented at the European Society for Medical Oncology, or ESMO, meeting in October. While Schmidt said Amgen's (AMGN) KRAS inhibitor Phase I data presented at the American Society of Clinical Oncology meeting validates MRTX849's potential mechanism of action, he sees a "lot of upside" priced in at the current valuation despite the remaining development risks. He also believes investor expectations have significantly increased ahead of Mirati's own Phase I data presentation in the second half of the year.
06/18/19
RHCO
06/18/19
DOWNGRADE
Target $48
RHCO
Hold
Array BioPharma downgraded to Hold from Buy at SunTrust
SunTrust analyst Peter Lawson downgraded Array BioPharma (ARRY) to Hold but raised his price target to $48 from $32 after the company announced that it is being acquired by Pfizer (PFE) at that price. The analyst notes that the 79% premium to the company's last closing price looks like a "fair valuation" based on his analysis of past comps and his M&A valuation model. Lawson adds that the the deal is "encouraging" within the biotech space with positive implications for other potential acquisition targets such as Agios Pharmaceuticals (AGIO) and Mirati herapeutics (MRTX) along with companies with strong chemistry such Incyte Corporation (INCY) and Exelixis (EXEL).
06/19/19
RILY
06/19/19
DOWNGRADE
Target $92
RILY
Neutral
Mirati Therapeutics downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Harshita Polishetty downgraded Mirati Therapeutics to Neutral from Buy with a $92 price target.
06/19/19
RILY
06/19/19
DOWNGRADE
Target $92
RILY
Neutral
B. Riley FBR downgrades Mirati to Neutral after 141% year-to-date rally
B. Riley FBR analyst Harshita Polishetty downgraded Mirati Therapeutics to Neutral from Buy while raising her price target for the shares to $92. The "de-risking" of MRTX849 is balanced by the 141% year-to-date rally in the shares, Polishetty tells investors in a research note. The analyst sees no significant share catalysts until 2020, which she believes increases "sell on the news" risk from the MRTX849 readout expected later this year.

TODAY'S FREE FLY STORIES

KPTI

Karyopharm

$9.01

0.69 (8.29%)

09:55
07/23/19
07/23
09:55
07/23/19
09:55
Options
Karyopharm put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AN

AutoNation

$46.03

4.02 (9.57%)

, DLPH

Delphi Technologies

$18.40

0.89 (5.08%)

09:55
07/23/19
07/23
09:55
07/23/19
09:55
Options
Early notable gainers among liquid option names on July 23rd »

Notable gainers among…

AN

AutoNation

$46.03

4.02 (9.57%)

DLPH

Delphi Technologies

$18.40

0.89 (5.08%)

SWK

Stanley Black & Decker

$148.45

7 (4.95%)

HAS

Hasbro

$117.00

8.46 (7.79%)

SHW

Sherwin-Williams

$474.81

20.19 (4.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 01

    Aug

  • 01

    Aug

  • 01

    Aug

  • 06

    Aug

  • 13

    Nov

09:55
07/23/19
07/23
09:55
07/23/19
09:55
Conference/Events
Senate Banking, Housing & Urban Affairs Committee to hold a hearing »

The Committee holds a…

LCI

Lannett

$7.82

-0.61 (-7.24%)

09:47
07/23/19
07/23
09:47
07/23/19
09:47
Hot Stocks
Lannett falls -5.1% »

Lannett is down -5.1%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NL

NL Industries

$4.80

(0.00%)

09:47
07/23/19
07/23
09:47
07/23/19
09:47
Hot Stocks
NL Industries falls -6.6% »

NL Industries is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JE

Just Energy

$3.94

-0.44 (-10.05%)

09:47
07/23/19
07/23
09:47
07/23/19
09:47
Hot Stocks
Just Energy falls -11.4% »

Just Energy is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PII

Polaris Industries

$87.80

5.265 (6.38%)

09:47
07/23/19
07/23
09:47
07/23/19
09:47
Hot Stocks
Polaris Industries rises 6.4% »

Polaris Industries is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

EDU

New Oriental Education

$104.82

6.585 (6.70%)

09:47
07/23/19
07/23
09:47
07/23/19
09:47
Hot Stocks
New Oriental Education rises 6.4% »

New Oriental Education is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

RLGY

Realogy

$6.61

1.44 (27.85%)

09:47
07/23/19
07/23
09:47
07/23/19
09:47
Hot Stocks
Realogy rises 28.2% »

Realogy is up 28.2%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

MGLN

Magellan Health

$68.15

(0.00%)

09:46
07/23/19
07/23
09:46
07/23/19
09:46
Periodicals
Magellan Health talks with Centerbridge hung up on price, Dealreporter says »

Centerbridge Partners and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOG

Harley-Davidson

$33.01

-1.24 (-3.62%)

09:45
07/23/19
07/23
09:45
07/23/19
09:45
Hot Stocks
Harley-Davidson CEO says profit margins to recover in FY20 with fixed EU tariffs »

Harley-Davidson CEO Matt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

09:45
07/23/19
07/23
09:45
07/23/19
09:45
General news
Richmond Fed Manufacturing Index Level to be reported at 10:00 »

July Richmond Fed…

09:45
07/23/19
07/23
09:45
07/23/19
09:45
General news
Existing Home Sales to be reported at 10:00 »

June Existing Home Sales…

CURLF

Curaleaf Holdings

$0.00

(0.00%)

09:40
07/23/19
07/23
09:40
07/23/19
09:40
Hot Stocks
FDA sends warning letter to Curaleaf over unapproved, 'misbranded' drugs »

The FDA posted on its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETN

Eaton

$79.54

(0.00%)

, SHLAF

Schindler

$0.00

(0.00%)

09:40
07/23/19
07/23
09:40
07/23/19
09:40
Hot Stocks
Eaton appoints Silvio Napoli to board of directors »

Eaton (ETN) announced…

ETN

Eaton

$79.54

(0.00%)

SHLAF

Schindler

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

AZN

AstraZeneca

$40.32

(0.00%)

, GM

General Motors

$39.86

(0.00%)

09:40
07/23/19
07/23
09:40
07/23/19
09:40
Options
Unusually active option classes on open July 23rd »

Unusual total active…

AZN

AstraZeneca

$40.32

(0.00%)

GM

General Motors

$39.86

(0.00%)

WHR

Whirlpool

$148.30

(0.00%)

HAS

Hasbro

$108.54

(0.00%)

KO

Coca-Cola

$51.25

(0.00%)

BIIB

Biogen

$232.46

(0.00%)

LMT

Lockheed Martin

$357.57

(0.00%)

ABT

Abbott

$88.08

(0.00%)

BYND

Beyond Meat

$193.91

(0.00%)

NVDA

Nvidia

$171.32

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 25

    Jul

  • 29

    Jul

  • 01

    Aug

  • 03

    Aug

  • 12

    Aug

  • 15

    Aug

  • 09

    Sep

  • 16

    Sep

  • 19

    Sep

  • 25

    Sep

  • 02

    Oct

  • 23

    Oct

09:40
07/23/19
07/23
09:40
07/23/19
09:40
General news
U.S. existing home sales preview: analysts expect a steady rate for June existing home sales »

U.S. existing home sales…

CABO

Cable One

$1,206.29

-11.71 (-0.96%)

09:38
07/23/19
07/23
09:38
07/23/19
09:38
Upgrade
Cable One rating change at Wolfe Research »

Cable One upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MFSF

MutualFirst Financial

$32.20

0.28 (0.88%)

09:37
07/23/19
07/23
09:37
07/23/19
09:37
Earnings
MutualFirst Financial reports Q2 EPS 66c, consensus 62c »

The Company's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$6.22

-0.38 (-5.76%)

09:35
07/23/19
07/23
09:35
07/23/19
09:35
Hot Stocks
CEL-SCI announces review published in International Immunopharmacology »

CEL-SCI Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$132.94

0.57 (0.43%)

09:33
07/23/19
07/23
09:33
07/23/19
09:33
Hot Stocks
United Technologies says 'very confident' about updated FY19 guidance »

Says: More good things to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

PKX

Posco

$49.91

-0.26 (-0.52%)

09:33
07/23/19
07/23
09:33
07/23/19
09:33
Upgrade
Posco rating change at Macquarie »

Posco upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

TRPX

Therapix Biosciences

$2.32

-0.02 (-0.85%)

09:33
07/23/19
07/23
09:33
07/23/19
09:33
Hot Stocks
Therapix Biosciences signs LOI to merge with Destiny Biosciences »

Therapix Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,985.93

21.15 (1.08%)

09:32
07/23/19
07/23
09:32
07/23/19
09:32
Recommendations
Amazon.com analyst commentary at BMO Capital »

Amazon.com Q3 consensus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

UGP

Ultrapar

$5.23

-0.165 (-3.06%)

09:32
07/23/19
07/23
09:32
07/23/19
09:32
Upgrade
Ultrapar rating change at Bradesco »

Ultrapar upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.